CSF1R and glioma: Further, CSF1R inhibition using the experimental compound PLX3397 has been shown to reduce disease progression and M2 gene signatures in preclinical models of glioma, and has enhanced efficacy over the broader spectrum tyrosine kinase inhibitors Vatalanib and Dovitinib [59].